Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lipocine Inc.LPCN · Entity 7696 | Director | June 04, 2025 | June 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lipocine Inc.
Report date June 04, 2025 · Filed June 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.20 · Expires 2035-06-04 | Direct | 11,526 |
Reported balance
After 2025-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-04 · Grant · Acquired 1,764 · Balance 11,526 F1: 100% vesting upon one year from date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% vesting upon one year from date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2025 Filed Jun 5, 2025 20:06 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantCommon Stock (Right to Buy) · Derivative | 1,764 | $3.20 Strike: $3.20 | $5,644.80 |
DisclosureSEC source: 0001641172-25-013793 · ownership.xml · derivative · entry 1 Fink Jeffrey Arvin · CIK 0001595930 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,526 Underlying: Common Stock · 1,764 shares Expires 2035-06-04 F1 · derivative.exercise_date: 100% vesting upon one year from date of grant. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 21:39 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantCommon Stock (Right to Buy) · Derivative | 1,764 | $7.05 Strike: $7.05 | $12,436.20 |
DisclosureSEC source: 0001493152-24-023207 · ownership.xml · derivative · entry 1 Fink Jeffrey Arvin · CIK 0001595930 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,938 Underlying: Common Stock · 1,764 shares Expires 2034-06-05 Read SEC document |
| May 10, 2023 Filed May 12, 2023 20:33 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantCommon Stock (Right to Buy) · Derivative | 30,000 | $0.27 Strike: $0.27 | $7,968.00 |
DisclosureSEC source: 0001493152-23-016684 · ownership.xml · derivative · entry 1 Fink Jeffrey Arvin · CIK 0001595930 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,000 Underlying: Common Stock · 30,000 shares Expires 2033-05-10 Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 15:33 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantCommon Stock (Right to Buy) · Derivative | 22,000 | $0.92 Strike: $0.92 | $20,240.00 |
DisclosureSEC source: 0001493152-22-016401 · ownership.xml · derivative · entry 1 Fink Jeffrey Arvin · CIK 0001595930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,000 Underlying: Common Stock · 22,000 shares Expires 2032-06-08 Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 18:42 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $1.26 Strike: $1.26 | $27,720.00 |
DisclosureSEC source: 0001638599-21-000537 · doc4_7259.xml · derivative · entry 1 Fink Jeffrey Arvin · CIK 0001595930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2031-06-09 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:07 UTC | Lipocine Inc. LPCN · Entity 7696 | Exercise / conversionRestricted Stock Unit · Derivative | 5,625 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000979 · doc4_6962.xml · derivative · entry 2 Fink Jeffrey Arvin · CIK 0001595930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,625 Underlying: Common Stock · 5,625 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO. F2 · derivative.expiration_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:07 UTC | Lipocine Inc. LPCN · Entity 7696 | Exercise / conversionCommon Stock | 5,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000979 · doc4_6962.xml · nonDerivative · entry 1 Fink Jeffrey Arvin · CIK 0001595930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F1 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F1 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. Read SEC document |
| June 10, 2020 Filed Jun 10, 2020 20:11 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.96 Strike: $0.96 | $21,183.80 |
DisclosureSEC source: 0001638599-20-000592 · doc4_6752.xml · derivative · entry 1 Fink Jeffrey Arvin · CIK 0001595930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 15:10 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $1.68 Strike: $1.68 | $16,800.00 |
DisclosureSEC source: 0001638599-19-000608 · doc4_6154.xml · derivative · entry 1 Fink Jeffrey Arvin · CIK 0001595930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| June 27, 2018 Filed Jun 28, 2018 16:29 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $1.33 Strike: $1.33 | $26,600.00 |
DisclosureSEC source: 0001638599-18-000700 · doc4_5502.xml · derivative · entry 1 Fink Jeffrey Arvin · CIK 0001595930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-27 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:14 UTC | Lipocine Inc. LPCN · Entity 7696 | Exercise / conversionRestricted Stock Unit · Derivative | 1,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-000024 · doc4_5175.xml · derivative · entry 3 Fink Jeffrey Arvin · CIK 0001595930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,625 Underlying: Common stock · 1,875 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 29, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. F4 · derivative.expiration_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 29, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:14 UTC | Lipocine Inc. LPCN · Entity 7696 | SaleCommon stock | 938 | $3.47 | $3,258.33 |
DisclosureSEC source: 0001638599-18-000024 · doc4_5175.xml · nonDerivative · entry 2 Fink Jeffrey Arvin · CIK 0001595930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 937 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Represents the weighted average price of shares sold at a price that ranged from $3.43-$3.54. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:14 UTC | Lipocine Inc. LPCN · Entity 7696 | Exercise / conversionCommon Stock | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-000024 · doc4_5175.xml · nonDerivative · entry 1 Fink Jeffrey Arvin · CIK 0001595930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). F1 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). F1 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). Read SEC document |
| January 26, 2017 Filed Jan 31, 2017 02:40 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantRestricted Stock Unit · Derivative | 7,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000127 · doc4_4500.xml · derivative · entry 1 Fink Jeffrey Arvin · CIK 0001595930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2027-01-25 F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit F2 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.